Efficacy and Safety of Insulin Aspart in MDI or CSII in Children Below 7 Years of Age With Type 1 Diabetes

• Status: Completed
• Trial end date: 2004-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Europe.

The aim of this trial is to investigate the efficacy of insulin aspart compared to soluble human insulin on blood glucose control in children below 7 years of age with type 1 diabetes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Insulin; Insulin Aspart; Insulin degludec, insulin aspart drug combination; Insulin, Globin Zinc; Insulin, Long-Acting

Criteria

Inclusion Criteria:

• Type 1 diabetes for at least 1 year

• HbA1c below 12.0%

• Treatment with regular human insulin and insulin NPH for at least 1 month

• Receive more than 2 injections daily

Exclusion Criteria:

• Receipt of investigational product within 6 months prior to trial participation

• Known or suspected allergy to investigational product

• Receipt of of insulin aspart within 3 months prior to trial participation